The antibiotic daptomycin is effective and well-tolerated in children for Methicillin-resistant Staphylococcus aureus (MRSA) infections, new research has found.
In a randomized, controlled clinical trial, the first of its kind, a multi-institution research team investigated daptomycin, part of a new class of antibiotics currently approved only for use in adults, which the Food and Drug Administration is currently reviewing whether to approve for use in children.
Study first author John Bradley, MD, said:
“The safety and efficacy of intravenous daptomycin was comparable to standard-of-care IV antibiotics used for hospitalized children, usually vancomycin or clindamycin for MRSA and cefazolin for methicillin-susceptible strains of S. aureus.
Daptomycin should provide a safe and effective alternative to vancomycin, clindamycin or linezolid for IV treatment of invasive MRSA skin infections. Concerns for vancomycin renal toxicity and clindamycin antibiotic resistance were not present. There was no evidence of daptomycin toxicity in the trial.”
Bradley is professor of clinical pediatrics, co-chief of the Division of Infectious Diseases at UC San Diego School of Medicine and director of the Division of Infectious Diseases at Rady Children’s Hospital-San Diego.
As its name suggests, MRSA is resistant to most common antibiotics and thus difficult to treat, particularly in children where it commonly causes complicated skin and skin structure infections.
Methicillin-resistant Staphylococcus aureus infections are commonly associated with patients in hospitals and nursing homes whose immune systems are weakened, but community-associated MRSA (CA-MRSA) is widespread, readily transmitted at daycare centers, playgrounds and in schools where children have frequent skin-to-skin contact, share toys that have not been cleaned and are more likely to have scrapes, abrasions and bites that offer potential infection entry points.
CA-MRSA usually causes skin infections but can lead to more serious consequences, such as pneumonia and infections of bones and joints. Daptomycin is active against MRSA and was approved for use in adults in 2003 for treatment of skin and skin structure infections, and for bloodstream infections three years later.
“Most news these days is about the declining utility of antibiotics as microbial resistance becomes more widespread and intractable,” said Bradley. “These findings are encouraging. Daptomycin appears to be a suitable, once-a-day alternative to existing antibiotics with harsher side effects.”
The new study was a prospective, randomized, investigator-blinded study that included more than 250 daptomycin-exposed children, ages 1 to 17, to document safety and efficacy of the antibiotic in treating pediatric skin and skin structure infections.
Dosing was based on adult experience, but researchers found that the younger the child, the more quickly their bodies eliminated daptomycin. Thus pediatric doses increased as the age of the research participants decreased.
John Bradley, Chad Glasser, Hernando Patino, Sandra R. Arnold, Antonio Arrieta, Blaise Congeni, Robert S. Daum, Tsoline Kojaoghlanian, Minjung Yoon, Diane Anastasiou, Dominik J. Wolf, Paula Bokesch
Daptomycin for Complicated Skin Infections: A Randomized Trial Pediatrics
Mar 2017, e20162477
Image: National Institutes of Health (NIH). Scanning electron micrograph of a human neutrophil ingesting MRSA.